CX Institutional grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 37.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 168 shares of the medical research company’s stock after buying an additional 46 shares during the quarter. CX Institutional’s holdings in Thermo Fisher Scientific were worth $49,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in TMO. FMR LLC boosted its stake in shares of Thermo Fisher Scientific by 33.5% in the 1st quarter. FMR LLC now owns 11,572,581 shares of the medical research company’s stock valued at $3,167,647,000 after buying an additional 2,900,868 shares during the period. Nuveen Asset Management LLC boosted its stake in shares of Thermo Fisher Scientific by 10,824.0% in the 2nd quarter. Nuveen Asset Management LLC now owns 1,928,966 shares of the medical research company’s stock valued at $566,498,000 after buying an additional 1,911,308 shares during the period. Jennison Associates LLC lifted its stake in Thermo Fisher Scientific by 2,589.9% during the second quarter. Jennison Associates LLC now owns 819,138 shares of the medical research company’s stock worth $240,564,000 after purchasing an additional 788,686 shares during the last quarter. Putnam Investments LLC lifted its stake in Thermo Fisher Scientific by 2,645.9% during the second quarter. Putnam Investments LLC now owns 720,795 shares of the medical research company’s stock worth $211,683,000 after purchasing an additional 694,545 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in Thermo Fisher Scientific by 361.8% during the first quarter. Marshall Wace LLP now owns 775,103 shares of the medical research company’s stock worth $212,161,000 after purchasing an additional 607,245 shares during the last quarter. Institutional investors and hedge funds own 88.18% of the company’s stock.
TMO stock opened at $283.64 on Friday. The business has a 50 day moving average price of $287.19 and a 200 day moving average price of $280.84. The stock has a market cap of $113.59 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 1.78 and a beta of 1.13. Thermo Fisher Scientific Inc. has a fifty-two week low of $208.34 and a fifty-two week high of $305.45. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, topping the consensus estimate of $3.01 by $0.03. The firm had revenue of $6.32 billion during the quarter, compared to analysts’ expectations of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The firm’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.75 earnings per share. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 12.25 EPS for the current year.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 2,271 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $298.00, for a total value of $676,758.00. Following the completion of the sale, the chief executive officer now owns 283,502 shares in the company, valued at $84,483,596. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jim P. Manzi sold 1,833 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total value of $500,280.69. Following the completion of the sale, the director now owns 28,592 shares of the company’s stock, valued at approximately $7,803,614.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,104 shares of company stock valued at $15,418,539. 0.45% of the stock is owned by company insiders.
Several research firms recently weighed in on TMO. ValuEngine cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Credit Suisse Group restated a “buy” rating and set a $310.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Needham & Company LLC boosted their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Monday, July 15th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average price target of $305.27.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: What is cost of equity?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.